Archives

  • 2018-07
  • 2018-10
  • 2018-11
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2019-12
  • 2020-01
  • 2020-02
  • 2020-03
  • 2020-04
  • 2020-05
  • 2020-06
  • 2020-07
  • 2020-08
  • 2020-09
  • 2020-10
  • 2020-11
  • 2020-12
  • 2021-01
  • 2021-02
  • 2021-03
  • 2021-04
  • 2021-05
  • 2021-06
  • 2021-07
  • 2021-08
  • 2021-09
  • 2021-10
  • 2021-11
  • 2021-12
  • 2022-01
  • 2022-02
  • 2022-03
  • 2022-04
  • 2022-05
  • 2022-06
  • 2022-07
  • 2022-08
  • 2022-09
  • 2022-10
  • 2022-11
  • 2022-12
  • 2023-01
  • 2023-02
  • 2023-03
  • 2023-04
  • 2023-05
  • 2023-06
  • 2023-08
  • 2023-09
  • 2023-10
  • 2023-11
  • 2023-12
  • 2024-01
  • 2024-02
  • 2024-03
  • 2024-04

    • br Tenofovir TFV an acyclic nucleoside phosphonate analogue

    2018-10-30


    Tenofovir raltegravir potassium (TFV), an acyclic nucleoside phosphonate analogue of 2′-deoxyadenosine, remains a first-line choice for the treatment of HIV infections under its prodrug form (i.e. tenofovir disoproxil fumarate, TDF). During the last decade, the use of TFV in pre-exposure prophylaxis (PrP) was first investigated as a vaginal microbicide gel (). More recently, rectal microbicide preparations and oral TDF alone or in combination with emtricitabine have been evaluated in PrP (), opening a new era in the fight against HIV. Clinical studies using TFV-based regimens in PrP provided inconsistent results, which have been primarily explained by poor adherence. The study by explored whether differences in the mechanism of TFV activation in peripheral blood mononuclear raltegravir potassium (PBMCs), vaginal and colorectal tissues exist. Also, they examined whether genetic variation in the nucleotide kinases that activate the drug could be responsible for the discrepant results observed in PrP studies using TFV-based regimens.
    Commentary While current combination antiretroviral treatment (ART) successfully suppresses human immunodeficiency virus (HIV) replication, it cannot eradicate the virus since HIV efficiently resides latently in some cellular reservoirs, mainly resting CD4 T cells but also dendritic cells and other cell types. It is known that HIV establishes a reservoir of replication-competent integrated provirus early after infection that is unresponsive to ART (Chavez et al., 2015; Martínez-Bonet et al., 2015; Siliciano and Siliciano, 2015). Although the mechanism of HIV persistence is not fully understood, proposed models focus on the continuous replenishment of the reservoir through ongoing virus production, perhaps in sites where ART penetration or activity is suboptimal. As an alternative, maintenance of the reservoir during ART can also occur through proliferation of latently infected cells. Models have also been proposed to explain persistent immune activation despite ART, and include HIV-induced gut damage that allows translocation of microbial products into the systemic circulation. Other persistent infections, such as cytomegalovirus (CMV) or Epstein–Barr virus (EBV), have also been linked to persistent immune activation. The measurement of HIV reservoir includes the accurate quantification of integrated HIV-1 DNA in peripheral blood and other cells or tissues (Archin et al., 2014). The study by Ruggiero and colleagues describes factors associated with the size of the HIV reservoir in a very well designed cross-sectional study of a carefully selected and homogeneous sample of HIV-1-infected patients with long-term plasma HIV-1 RNA suppression under ART (Ruggiero et al., 2015). It is important to note that the study cohort was uniform with respect to the initial first-line antiretroviral regimen and absence of viral blips for up to 14years. The size of the reservoir was measured by the quantification of integrated HIV-1 DNA as well as by 2-long terminal repeat circular HIV-1 DNA. Investigated factors associated with the reservoir included residual plasma HIV-1 RNA and markers of immune activation on CD4 and CD8 T cells, and also the quantification of soluble CD14 as a marker of monocyte/macrophage activation. The main finding of this study was a positive association between the levels of integrated HIV-1 DNA in peripheral blood and the frequency of CD8 T cells expressing HLA-DR/DP/DQ. Furthermore, the lack of association between integrated HIV-1 DNA load and CD8 and CD4 cells expressing CD38 indicates that the association involves a distinct T cell activation profile. The immune activation marker, HLA-DR/DP/DQ, can therefore indirectly estimate the HIV reservoir in eradication strategies. This paper contributes to evidence that a complex interplay between HIV-1 persistence and immune activation continues over many years despite stably suppressive ART. Although the function of CD8 T cells expressing HLA-DR/DP/DQ (without CD38) needs to be further studied, both regulatory and effector functions may play a role. Crucially, CD8+HLADR/DP/DQ+ cells may stimulate HIV-infected CD4 cells, causing expansion of the reservoir. As the authors mentioned, it will be important to determine the antigenic specificity of these cells and any possible activity against persistent viruses such as CMV and EBV. These infections were not commonly detected in the cohort studied and this observation would suggest immunological control. As the authors recommend, it will be important to study CD8+CD38−HLA-DR/DP/DQ+ cells specifically, as they are preferentially generated in response to low antigenic stimulation and may play a role as elite controllers, suppressing HIV replication as well as clearing hepatitis C infection.